China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up

Ascentage Pharma International

20/08/2026 24:17

Overview
China oncology drug developer's H1 revenue rose 29% yr/yr on higher product sales
Net loss widened as operating expenses and R&D spending increased
Company removed B marker from stock short name after meeting higher listing requirements

Outlook
Ascentage Pharma will advance enrollment in Olverembatinib's POLARIS-1, POLARIS-2 and POLARIS-3 trials in 2026
Lisaftoclax plans clinical studies in venetoclax-failed patients and continued enrollment in four GLORA trials in 2026
Pelcitoclax plans to initiate a China Phase I study of monotherapy and combinations in R/R AML

Result Drivers
PRODUCT SALES - Co said revenue growth was mainly driven by higher product sales, especially from Olverembatinib and Lisaftoclax
R&D SPENDING - Co said increased research and development expenses were mainly due to progress in ongoing global clinical trials
LISAFTOCLAX COMMERCIALIZATION – Selling and distribution expenses rose 64.3% to RMB 226.4 mln on increased marketing and promotion investment

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 302.20 mln
 
H1 Net Loss Attributable to Ordinary Equity Holders
 
RMB 816.70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Ascentage Pharma Group International is HK$90.70, about 160.8% above its August 19 closing price of HK$34.78

Reuters Recommended Reads
Aug 19 - Sino Biopharmaceutical H1 revenue up 10.6% on innovative drug sales
Aug 19 - China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs
Aug 17 - China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-19/82f37f51-ec5f-4c15-9a91-9d176582431a.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)